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1. Introduction 
After a variable or silent initial course, MS patients often enter a progressive neurological 
decline leading to permanent clinical disability. Axonal loss is considered the major factor 
behind this process. Elucidating the etiology and pathogenesis of this phenomenon is critical 
to developing treatments for progressive MS. Here we discuss pathologic presentation of 
axonal loss in MS, patterns of axonal loss at certain disease stages, and evidence that axonal 
loss in MS progresses independently of clinical relapses but coincides strongly with 
inflammation. Mechanisms behind axonal loss in MS include T cell attack, reactive nitrogen 
species-induced damage, loss of myelin (demyelination), and loss of trophic support from 
oligodendrocytes. Also, we will review animal models of neurodegeneration that share 
similar disease features with MS axonopathy. Finally, we will consider the progress of 
therapeutic strategies aimed at axonal preservation in MS including remyelination 
enhancement, blockage of Na+ channels and prevention of free radical formation. 
2. Clinical overview of MS 
In about 85% of patients, MS follows a biphasic course. In the first phase or relapsing-
remitting multiple sclerosis (RRMS), patients suffer transient bouts of neurological deficit 
caused by neuroinflammation followed by rapid recovery (Noseworthy et al., 2000). The 
pathologic hallmark of RRMS attacks is inflammatory demyelinated foci or lesions in the 
white and gray matter of the central nervous system visible on MRI. The clinical 
manifestations of RRMS attacks are variable from patient to patient, and may include 
paraesthesia (numbness), diplopia (double vision), scotoma (visual anomalies), sensory and 
motor disorders of limbs and cerebellar incoordination (lack of balance). In many cases, after 
a variable amount of time (approximately 10-20 years) patients will enter a progressive 
phase of the disease This more severe second stage is characterized by an irreversible 
neurological decline culminating in severe disability. Once this second phase is identified, 
patients exhibiting this biphasic couse are diagnosed with secondary progressive multiple 
sclerosis (SPMS). In some cases, patients will exhibit only a progressive phase of disease, 
which represents primary progressive multiple sclerosis (PPMS). These patients have 
symptomatic onset of the progressive form of the disease with no prior history of 
neuroinflammatory attacks. 
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3. History of axonal pathology in MS, 1868-1990s 
Axonal pathology in multiple sclerosis was described by Charcot in 1868 (Charcot, 1868). 
From Charcot’s identification of axonal damage up to the 1990s, two general observations 
on axonal pathology in multiple sclerosis come up frequently in the literature (Charcot, 
1877; Dawson, 1916; Buzzard and Greenfield, 1921; Greenfield and King, 1936; Putnam, 
1936; Adams and Kubik, 1952; Peters, 1968; Shintaku, et al., 1988). First, MS lesions exhibit 
abnormal axonal anatomy. Second, Wallerian degeneration, the process of cellular 
degradation and necrosis far from zones of demyelination, is prevalent in long-standing MS 
cases. As more precise histological techniques have arisen, these broad features have been 
elaborated at the molecular level.  
4. Histology of axonal pathology 
4.1 Axonal injury 
Axonal injury is defined as pathological changes in the cytoarchitecture of an axon 
happening within a short time window before axonal death (Gentleman et al., 1993). Because 
debris of degenerating axons is rapidly cleared by CNS scavenger cells, quantification of 
axonal injury can often underestimate axonal loss accrued over long stretches of time (Trapp 
and Nave, 2008). Disturbance of fast axonal transport is the most accurate and sensitive 
method of determining axonal injury (Cochran et al., 1991; Gentleman et al., 1993; Ohgami et 
al., 1992, Sherriff et al., 1994a). Due to dystrophic changes, fast axonal transport mechanisms 
are unable to efficiently move cellular substances along the length of the axon. These 
substances accumulate as focal concentrations (spheroids), continuously and 
discontinuously, at certain points along the length of the axon (Figure 1). Axonal injury 
ranges from minor changes in the axoplasmic membrane to severe distentions as a result of 
disrupted fast axonal transport (Ferguson et al., 1997).  
  
Fig. 1. Axonal injury in an active multiple sclerosis lesion. Immunocytochemistry staining 
with an anti-amyloid precursor protein (APP) antibody reveals stained spheroid elements 
40-80 µm in diameter or in a beaded string-like appearance along the length of axons. 
Axonal dystrophy has caused these accumulations by interfering with fast axonal transport 
(from Ferguson et al., 1997). 
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4.2 Axonal transection 
Axonal transection in MS has been a main research focus since its discovery in the late 1990s 
(Trapp et al., 1998; Lovas et al., 2000; Peterson et al., 2001). If axonal dystrophy exceeds a 
certain threshold, the axon cytoskeleton may dissolve resulting in a characteristic bulblike 
formation known as a transection (Figure 2). Axonal transections are also referred to as 
axonal end-bulbs, terminal ovoids or spheroids, or terminal swellings. Axonal end-bulbs are 
morphologically ovoid in shape. In acute MS white matter lesions, swellings average 40-80 
µm in diameter (Trapp et al., 1998). They are typically smaller in chronic lesions. 
Transections are positively identified by confirming the presence of only a single axonal 
connection to the swelling. Swellings that have two axonal connections represent 
intracellular protein accumulations that are pathological but not indicative of breakage 
(Ferguson etl al. 1997). Immunohistochemistry using anti-amyloid precursor protein (APP) 
antibodies is a useful method for identifying axonal transections (Sherriff et al., 1994). APP 
and other fast axonal transport proteins accumulate in the end-bulb. Staining for non-
phosphorylated neurofilament also detects ovoid formation (Sternberger et al., 1983). 
Although demyelination is a key etiological factor in transection, end-bulbs may or may not 
be encircled with myelin (Trapp et al., 1998; Bjartmar et al., 2001; Aboul-Enein et al., 2006). 
 
Fig. 2. Axonal transections in a multiple sclerosis lesion. Non-phosphorylated neurofilament 
is green and myelin is red. An end-bulb (arrow) retains a single axonal connection and is 
therefore terminal. Axons stain positive for non-phosphorylated neurofilament where 
myelin is discontinuous (Adapted from Trapp and Nave, 2008).  
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5. Molecular markers of axonal pathology 
Immunocytochemistry staining of amyloid precursor protein (APP) or non-phosphorylated 
neurofilament is commonly used to identify axonal injury and axonal transection. Staining 
of these factors is often used in conjunction with antibodies to myelin antigens (i.e. myelin 
basic protein) in order to qualitatively determine the degree of demyelination coincident 
with axonal damage. Although less sensitive and accurate than immunocytological 
methods, Bielchowsky silver stain is a classic method still used to identify the general 
character of nerve fibers.  
5.1 Bielchowsky silver stain 
Before the era of immunocytochemistry, neurological studies relied on silver stains to 
visualize axonal pathology. Developed by Max Bielchowsky, the technique is a modified 
version of Santiago Ramón y Cajal’s method of impregnating nerve fibers with silver. The 
method became known as the Bielchowsky silver stain. The classic technique is still used 
today to describe nerve fibers. Bielchowsky staining is particularly useful in identifying 
general axon morphology, such as axonal caliber and Wallerian degeneration (Galeano and 
Vav Ferriera, 1957; Wakita et al., 2002). However, more sensitive laboratory techniques are 
needed in order to detect axonal injury and transection. 
5.2 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy is used to non-invasively measure chemical-pathologic changes in 
distinct brain slices of MS patients. Most notably, NMR studies have demonstrated whole 
brain reductions in the neuro-axonal marker N-acetylaspartate (NAA) in MS patients 
compared with normal controls (Gonen et al., 2000). Because differences in NAA levels 
compared to controls are greater amongst older than younger MS patients, this neuronal 
marker is useful in charting the course of neurodegeneration in the disease (Gonen et al., 
2000). Reduced levels of NAA are detectable in inflammatory foci early on in the 
relapsing/remitting stage of the disease (Matthews et al., 1996). Moreover, decreased NAA 
in the normal-appearing white matter (NAWM) of relapsing/remitting and progressive 
patients suggests that the neurodegenerative process is not confined to inflammatory lesions 
(Tourbah et al., 1996). The ability to precisely localize changes in compounds such as NAA 
has made serial NMR of distinct brain slices a useful tool in human clinical trials looking at 
drug efficacy (Destefano et al., 2007). Serial NMR has also been effective in tracking 
pathologic changes in animal models of MS, such as experimental autoimmune 
encephalomyelitis (EAE) (Stewart et al., 1991).  
5.3 Amyloid precursor protein (APP) 
Detection of amyloid precursor protein (APP) positive foci within axons indicates axonal 
injury in MS lesions (Gehrmann et al., 1995; Ferguson et al. 1997). This method derives from 
studies on axonal damage resulting from traumatic head injury (Gentleman et al.). APP is an 
integral membrane protein expressed primarily in neuronal synapses. Although its function 
is unknown, APP is thought to be associated with the endosomal/lysosomal system, 
synapse formation, neural plasticity, and iron transport (Haass et al., 1992; Ferreira et al., 
1993). Normally, APP is transported by fast axonal transport along the axon (Koo et al., 1990) 
www.intechopen.com
 Mechanisms and Patterns of Axonal Loss in Multiple Sclerosis 
 
125 
and is undetectable by immunocytochemical methods. However, disruptions in the integrity 
of axonal structure inhibit the smooth transport of APP. Subsequently, APP builds up at 
certain points along the axon. Axonal damage appears microscopically as distinct, elongated 
APP+ blots following the course of the axon, or a succession of discontinuous APP+ 
punctate dots that look as if they are lodged within the axon (Figure 1). 
Immunocytochemistry for APP is a useful method of detecting axonal injury in human and 
animal nerve tissue preparations (Sherriff et al., 1994b; Herrero-Herranz et al, 2008). Staining 
of other fast axonal transport substances is often used to determine or verify axonal injury, 
including synaptic vesicle terminal or synaptophisin protein (SPY) (Frischer et al. 2009).  
5.4 Non-phosphorylated neurofilament 
Detection of non-phosphorylated neurofilaments along axons or collected at the site of 
axonal transections is another efficient method of identifying axonal damage in MS 
(Sternberger et al., 1983; Trapp et al; 1998). Neurofilament is the principal structural 
constituent of the axon, accounting for its shape and integrity. Phosphorylation of 
neurofilament ensures proper extension of neurofilament side arms (Dutta et al., 2006). This 
process enhances axon diameter, neurofilament spacing, and conduction velocity of the 
axon. Normally, axons are insulated by myelin, a multilayered lipid sheath which enhances 
the conduction velocity of nerve impulses and protects the axonal cell membrane from the 
extracellular environment. Demyelination exposes the axolemma to phosphatases which 
dephosphorylate neurofilament fibers and subsequently induce structural damage. 
Dephosphorylated neurofilament fibers show fragmentation and decreased spacing 
between fibers due to reduced side-arm extensions (Dutta et al., 2006). 
Demyelination/dysmyelination has also been shown to reduce axonal caliber and number 
of phosphorylated neurofilaments in animal models, as well as increase the number of non-
phosphorylated neurofilament epitopes (deWaegh et al., 1992, Hsieh S-T et al. 1993). Double-
label immunohistochemistry for non-phosphorylated neurofilament and myelin antigens is 
an effective method for identifying axonal pathology concomitant with demyelination 
(Trapp et al., 1998). In addition, axonal spheroids have been shown to contain many other 
substances (Table 1). Moreover, axonal spheroids are detectable in a number of other 
neurological conditions using immunocytochemistry for specific substances (Table 1). 
6. Patterns of axonal pathology in MS 
Although clinically axonal loss is being revealed as a pathological process independent of 
acute relapses (Kremenchutzky et al., 1996), inflammation and neurodegenerative processes 
interface to accelerate neuronal death in MS (Frischer et al., 2009). A comprehensive picture 
of the pathological changes taking place in axons in MS considers CNS lesions and normal 
brain and spinal cord tissue. Pathology in MS axons include dystrophic changes (i.e. 
thinning), non-terminal swellings (intracellular accumulations), intracellular vacuolization 
(Kornek et al., 2001; Evangelou et al., 2005; Miller and Leary, 2007) and end-bulb formation 
(transection). Distinct patterns of axonal pathology are present in different 
histopathogenetic stages of MS lesions (Table 2, Han et al., 2008; Frischer et al., 2009). Active 
and chronic MS white matter lesions exhibit axonal injury profiles corresponding with the 
degree of inflammation (Bitsch et al., 2000; Herrero-Herranz, 2008; Frischer et al., 2009). 
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Aging MAP1A, tau, phosphorylated tau, 
synaptophysin, Hsp40, Hsp60, 
Hsp90, Hsp27, Hsp70, Hsp32, alpha 
ß-crystallin, ubiquitin, APP
(Fukuda et al., 2005; Dickson et al., 
1990) 
Alzheimer’s 
disease 
NF-M, ChAT, phosphorylated tau (Nakazato et al., 1984; Stokin et al., 
2005)
Amyotrophic 
lateral sclerosis 
Kinesin, peripherin, neurofilament-
M and -H, ßIII-tubulin, STOP 
proteins, galectin-1, superoxide 
dismutase-1, APP, 1-hexitol-lysine 
(AGE); chromogranin A
(Kato et al., 2001; Kikuchi et al., 2002; 
Letournel et al., 2003; Nakazato et 
al., 1984; Sasaki and Iwata, 1999; 
Shibata et al., 1996; Toyoshima et al., 
1998; Yasuhara et al., 1994) 
Brain abscess APP (Ohgami et al., 1992)
Central pontine 
Myelinolysis 
APP (Medana and Esiri, 2003) 
CNS HIV 
infection 
APP, ubiquitin (Gray et al., 1998; Izycka-
Swieszewska et al., 2000; Medana 
and Esiri, 2003; Raja et al., 1997; 
Smith et al., 1990)
CNS Malaria APP (Medana and Esiri, 2003) 
Creutzfeldt-Jakob 
disease 
NF-H, APP (Guiroy et al., 1989; Kobayashi et 
al., 2008; Liberski and Budka, 1999) 
Frontotemporal 
dementia  
NF-H, tubulin (Zhou et al., 1998)
Hallervorden-
Spatz syndrome 
APP, iron II, synuclein (alpha, beta, 
and gamma) 
(Galvin et al., 2000; Neumann et 
al., 2000; Newell et al., 1999; 
Ohgami et al., 1992)
Infantile 
Neuroaxonal 
Dystrophy 
Neurofilament (Nakazato et al., 1984) 
Multiple Sclerosis Neurofilament, APP, N type calcium 
channel subunit alpha 1B (Cacna1b), 
oxidized phospholipids, 
synaptophysin
(Ferguson et al., 1997; Ghosh et al., 
2004; Haider et al., 2011; Kornek et 
al., 2001; Raine and Cross, 1989; 
Trapp et al., 1998)
Multiple System 
Atrophy  
Chromogranin A, NF-H (Nakazato et al., 1984; Yasuhara et 
al., 1994)
Parkinson’s 
disease 
alpha-synuclein, phosphorylated 
tau, alphaß-crystallin, Bcl-x, parkin, 
chromogranin A, ubiquitin
(Choi et al., 2001; Choi et al., 2000; 
Jellinger, 2000; Yasuhara et al., 
1994)
Parkinsonism-
dementia of Guam
tau, ubiquitin, phosphorylated tau (Schwab et al., 1997)
Periventricular 
leukomalacia  
APP, fractin (Arai et al., 1995; Haynes et al., 
2008)
Stroke APP, chromogranin A (Ohgami et al., 1992; Yasuhara et 
al., 1994)
Traumatic brain 
injury  
APP, synuclein (Gentleman et al., 1993; Medana 
and Esiri, 2003; Newell et al., 1999; 
Raisanen et al., 1999)
Table 1. Neurological conditions presenting with axonal spheroid formation. 
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Lesion Subtype Active Lesions 
 
Chronic Active 
Lesions 
Chronic Inactive 
Lesions 
Myelin in lesion 
core 
Present Absent Absent 
Active 
demyelination 
Present Margins: Present 
Cores: Absent 
Absent 
Inflammation Extensive 
throughout 
Concentrated at 
margins 
Comparable to aged-
matched normal 
appearing white 
matter controls from 
non-MS brains 
Axonal transections Extensive 
throughout, arge in 
diameter 
Margins: diffuse, 
small in diameter 
Core: few 
- Few 
- similar to aged-
matched controls 
Axonal character Continuous non-
phosphorylated 
neurofilament along 
axons (intact 
demyelinated 
axons), axonal 
thinning 
Same as active 
lesions but less 
prevalent and 
restricted mainly 
to lesion margins 
- Unusually thick, 
demyelinated, axons 
- Occasional 
synaptophisin build 
up, 
 - Occasional axonal 
tract degeneration 
Axonal cell 
associations 
- Cytotoxic T cells 
- Microglia and 
macrophages 
around 
degenerating axons 
Same as active 
lesion but cell 
associations found 
mostly in lesion 
margins 
Comparable to aged-
matched normal 
appearing white 
matter controls from 
non-MS brains 
Table 2. Axonal pathology within different MS white matter lesion subtypes.  
6.1 Active lesions 
Active white matter MS lesions are lesions undergoing demyelination with heavy 
infiltration of HLA-II reactive macrophages, microglia and leukocytes. In short, these lesions 
are white matter areas undergoing a hostile immune reaction. In active lesions, reactive 
CD8+ cytotoxic T cells and macrophages attack the myelin sheath of axons. Microglia and 
macrophages are commonly found surrounding degenerating axons (Trapp et al., 1998; 
Barnett and Prineas, 2004). Macrophages phagocytose and clear myelin debris resultant 
from the destruction of myelin (Prineas and Wright, 1978; Ferguson et al., 1997; Barnett and 
Prineas, 2004). 
Active lesions display numerous small-caliber axons and relatively large transections 
throughout their entirety (Frischer et al., 2009). The neurofilament fibers of dystrophic axons 
and swellings are commonly non-phosphorylated. Axonal spheroids or ovoids are usually 
positive for both non-phosphorylated neurofilament and amyloid precursor protein (APP), 
although ovoids positive for non-phosphorylated neurofilament positive and negative for 
APP have been reported (Ferguson et al., 1997). Thin axons and transections may or may not 
be ensheathed with myelin (Trapp et al., 1998; Bjartmar et al., 2001), although contiguous 
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demyelination is a common feature. Lengths of non-phosphorylated axons with intact 
myelin occasionally extend outside of the lesion zone (also observed in chronic lesions) 
(Trapp et al., 1998). The degree of axonal pathology (i.e. number of ovoids, concentration of 
APP) correlates with the amount of inflammatory infiltrates within the lesion (Frischer et al., 
2009).  
6.2 Chronic active lesions 
Chronic active lesions are punched-out, demyelinated lesions with inflammation and active 
demyelination occurring mainly at their margins. Inflammation concentrated in the margins 
of chronic lesions is comparable to that in the cores of active lesions. For this reason they 
have been called “expanding lesions” (Frischer et al., 2009). In their cores, chronic lesions 
contain fewer macrophages and T cells than active lesions. Inflammation in the cores of 
chronic active lesions is reduced compared to active lesions, and often non-existent. HLA-II 
reactive microglia and astrocytes are numerous in the borders of chronic lesions where 
inflammation and demyelination are prevalent.  
Chronic lesions display fewer and smaller-diameter axonal swellings in their cores and 
margins than active lesions (Ferguson et al., 1997). In chronic lesions, axonal ovoids are most 
numerous in the margins where inflammation is concentrated, further emphasizing the 
relationship between axonal injury and the inflammatory reaction. Likewise, the actively 
demyelinating margins of chronic lesions display far more axonal ovoids than their cores 
(Trapp et al., 1998). However, since it is estimated that chronically demyelinated lesions 
show 60-70% loss of axons (Mews et al., 1998), the lack of core axonal injury may reflect 
axonal destruction and loss. Axonal associations with leukocytes and monocytes are similar 
to those seen in active lesions, although these cell-to-cell interactions are concentrated at the 
margins where inflammation is most active.  
6.3 Chronic inactive lesions 
Chronic inactive lesions are punched-out, demyelinated lesions with no detectable 
inflammatory or actively demyelinating processes. Chronic inactive lesions display severe 
tissue vacuolization and diffuse astrocytosis. They contain few HLA-II reactive cells and are 
generally hypocellular (Frischer et al., 2009). 
Chronic inactive lesions contain few axonal spheroids in their cores and margins. Axons 
within chronic inactive lesions appear abnormally thicker than those within chronic active 
lesions, possibly due to axonal swelling associated with chronic disease processes (Shintaku 
et al., 1988). The degree of axonal injury and inflammation in chronic inactive lesions is equal 
to that seen in normal appearing white matter from aged-matched, non-MS controls 
(Frischer et al., 2009). This suggests that in these embattled lesions the disease process has 
died out.  
6.4 Normal appearing white matter (NAWM): Relapsing/remitting and progressive 
patients 
Axonal injury in the NAWM of progressive patients is more substantive compared to 
relapsing/remitting patients (Frischer et al., 2009). NAWM of progressive patients is 
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characterized by diffuse inflammation, axonal injury and microglia activation. Diffuse 
white matter injury can be profound in these patients even with a relatively minor focal 
lesion load (Kutzeinigg et al., 2005). Similarly, focal demyelinating lesions show only a 
marginal correlation with inflammation in NAWM and cortical regions (Kutzeinigg et al., 
2005). This supports the idea that the formation of demyelinated foci occurs 
independently of inflammatory damage taking place in normal brain regions. However, 
pathologic changes occurring in the NAWM do so against a background of diffuse 
inflammation (Kutzeinigg et al., 2005). This suggests that with disease chronicity 
inflammatory cells escape the control of the peripheral immune system and slowly 
accumulate in the whole brain. Over time, these infiltrates may inflict massive, cumulative 
white matter damage on a global scale, which manifests clinically as the progressive 
phase of the disease (Kutzeinigg et al., 2005).  
6.5 Axonal pathology in relapsing/remitting and progressive MS 
Up until now, we have considered axonal pathology in lesions at different pathogenic stages 
of MS. Here, we will discuss axonal pathology as it occurs in patients with 
relapsing/remitting, primary progressive, and secondary progressive forms of MS.  
In all MS subtypes (relapsing/remitting, primary and secondary progressive), the amount 
of axonal injury in any demyelinated lesion is tightly correlated with the degree of 
inflammation present in the lesion (Frischer et al., 2009). This supports the idea that an 
inflammatory reaction is chiefly responsible for axonal injury in demyelinated zones. In 
line with this idea, active lesions show the highest density of axonal injury (Trapp et al., 
1998). Relapsing/remitting MS patient possess a higher number of active lesions than 
patients of any other disease phase. Because of this, relapsing/remitting patients have a 
higher degree of axonal injury than patients with progressive forms of the disease 
(Frischer et al., 2009).  
In spite of this, lesions at the same level of activity exhibit no significant differences in 
axonal injury between relapsing/remitting, primary progressive, and secondary progressive 
MS patients. That is, an active lesion from a relapsing/remitting patient contains the same 
extent of axonal injury as an active lesion from a progressive patient. The one important 
exception is with normal appearing white matter (NAWM) which shows a greater extent of 
axonal injury in progressive patients than in relapsing/remitting patients (Frischer et al., 
2009). As discussed above, one explanation for this is that in progressive patients 
inflammatory cells accumulate in the whole brain and inflict massive white matter damage, 
whereas in relapsing/remitting patients axonal injury is limited to inflammatory 
demyelinating foci (Kutzeinigg et al., 2005). In summary, relapsing/remitting patients tend 
to exhibit high axonal injury associated with inflammatory demyelinating foci, whereas 
progressive patients tend to exhibit diffuse white matter damage that may be secondary to 
global inflammation.  
Lesions from patients with progressive forms of MS (primary or secondary progressive) 
exhibit highly variable levels of axonal injury. However, the presence or absence of ongoing 
inflammation in progressive MS brains correlates with the extent of axonal damage. In order 
to demonstrate this, Frischer et al. classified progressive patients in a large post-mortem 
histological study as either pathologically active or pathologically inactive. Brains of 
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pathologically active patients revealed the persistence of active or chronic active lesion 
activity (lesions with inflammatory activity). Brains of pathologically inactive patients 
contained inactive lesions only. Frischer et al. found that pathologically inactive patients 
lived significantly longer than pathologically active patients (mean 76 yrs., range 64-84 vs. 
mean 53 yrs., range 28-82). Chronic inactive lesions in the pathologically inactive group 
contained axonal injury equal to that of aged-match controls. Conversely, chronic inactive 
lesions in pathologically active patients exhibited significantly more axonal injury than 
those of the pathologically inactive group. This data suggests that in progressive MS axonal 
injury is intrinsically tied to an ongoing inflammatory reaction. In a subset of MS patients 
with significantly reduced axonal injury, the inflammatory reaction appears to die down to 
the level of aged-matched controls (Frischer et al., 2009). 
6.6 Axonal loss as a distant pathological process  
Axonal loss is considered the primary cause of permanent clinical disability in patients with 
MS. The fact that axonal loss may approach 30-40% (Ganter et al., 1999) in the spinal cord 
and possibly as high as 60-70% in lesioned white matter tissue (Mews et al., 1998) 
demonstrates the severity of neurodegeneration in chronic disease pathogenesis. Evidence 
that the neurodegenerative component ensues independently of inflammatory disease 
derives from clinical data. These data include irresponsiveness of progressive MS to 
immunomodulatory therapies and inconclusive reports that pharmacological treatment of 
inflammatory bouts lessens morbidity and delays time of onset of progressive forms of the 
disease (Fisher et al., 2008; Fisniku et al., 2009).  
Striking evidence that uncouples acute relapses and neurodegeneration comes from case-
control studies examining the time of onset of progressive disability across different types of 
MS. In a poignant retrospective study using large cohorts of over 1000 patients per arm, 
Kremechutzky et al. showed that relapsing/remitting, primary progressive, and secondary 
progressive patients began irreversible neurological decline at about the same time (~2.6 
years mean difference between time of onset). The clinical disability measured by the 
Expanded Disability Status Scale was similar across these patient groups and irrespective of 
preceding or subsequent relapse events.  
Studies of the histopathogenesis of MS also indicate axonal loss as a distinct disease 
mechanism. Identification of degenerating nerve fibers outside inflammatory foci in the 
normal appearing white matter (NAWM) of post-mortem MS brains shows that the 
neurodegenerative process can occur independently – at least topgraphically– of 
inflammation and demyelination (Bjartmar et al., 2001). However, there is a strong 
correlation between the degree of axonal injury and inflammation in all MS lesion stages 
and normal appearing white matter (Bitsch et al., 2000; Herrero-Herranz, 2008; Frischer et al., 
2009). Moreover, progressive patients exhibit extensive neurodegeneration against a 
background of massive inflammation and glial activation (Kutzeinigg et al., 2005). Although 
it is unclear precisely how the extent of inflammation definitely relates to axonal loss in MS. 
In the same way, the extent of axonal injury and the autoimmune inflammatory process 
concomitantly diminish to the level of aged-matched controls as the disease progresses 
(Frischer et al., 2009). 
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7. Mechanisms of axonal injury 
Extensive research has focused on determining the mechanisms responsible for axonal loss 
and findings have identified several pathogenic phenomena that might be responsible. 
Some mechanisms are thought to initiate other pathological events downstream, ultimately 
leading to the demise of the axon. Initiating factors include inflammatory and 
immunological attack of axons, exposure of demyelinated axons to the excitotoxic MS lesion 
environment, and loss of trophic support by oligodendrocytes and other resident CNS cells 
affected by the inflammatory milieu. These initiating factors are capable of setting up an 
energy imbalance in the axon, leading to a state of virtual hypoxia. The result is the eventual 
dissolution of the axonal cytoskeleton at the site of injury. Axonal damage can also cause a 
type of degradation distal to the site of injury referred to as Wallerian degeneration.  
7.1 CD8+ cytotoxic T lymphocytes 
Major histocompatibility complex (MHC) class I-restricted CD8+ cytotoxic T lymphocytes 
(CTLs) are thought to directly attack axons and dendrites (neurites) and neuronal soma in 
MS lesions. These cells outnumber class-I restricted CD4+ T cells approximately 10 fold in 
actively demyelinating MS white matter (Booss J et al., 1983; Gay FW et al., 1997). 
Interleukin-2 (IL-2), a cytokine released by CD4+ T helper cells, along with MHC class-I-
antigen recognition, initiates differentiation of CD8+ T cells into effector CTLs. Because IL-2 
concentrations are increased in the serum and CSF of MS patients (Gallo et al., 1992), it is 
likely that in lesions CD8+ T cells differentiate into effector CTLs by recognizing MHC class 
I-peptide on CNS cells and receiving the IL-2 second signal. Because the CD8+ CTLs 
constitute a clonally expanded population, these effector cells are highly specified and 
reactive against a single antigen.  
Activated CTLs are capable of causing detrimental damage to axons. CTLs have been shown 
to transect MHC class I-induced axons in culture (Medana I et al., 2001). Axons and dendrites 
damaged by allogenic attack in vitro display degeneration characteristic of axonal injury 
(Manning et al., 1987). In MS lesions, effector CTLs directly contact dystrophic axons and 
terminal ovoids (Neumann et al., 2002). However, lesions at exceptionally early stages of 
demyelination contain few T or B cells (Henderson et al., 2009). Once in contact with the axon, 
cytotoxic granules of CTLs polarize toward the surface (Figure 3). Perforin, an effector 
substance contained within these granules, polymerizes to form a pore that is inserted into the 
axonal membrane, allowing water and salt to flow into the axon. Na+ influx initiates reversal 
of the Na+/Ca++ exchanger, leading to a vicious cycle of increased Ca++ intracellular 
accumulation (Smith et al., 2001). Granzyme, a second CTL effector substance, degrades axonal 
proteins, disrupting fast transport and potentially triggering apoptosis (Figure 4). 
7.2 MHC induction 
In the CNS, disparate cell lineages interact to ensure that the powerful immune defenses of 
the brain are not misguided. Autoimmune diseases such as MS must overcome these cell-to-
cell interactions that hold the immune system at bay. For example, neurons are able to 
suppress MHC expression in surrounding cells, in particular microglia and astrocytes, 
through ligand-receptor interactions (Neumann H, 2001). However, disruption of Na+ 
membrane-dependent electrical activity has been shown to decrease the efficacy of these 
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interactions and increase induction of MHC class-I by inflammatory cytokines such as 
interferon-. In the case of MS, demyelination and axonal injury are both capable of 
disrupting Na+ flow in axons. This helps explain the increased CTL differentiation and 
activation of microglia and astrocytes. Moreover, MHC class-I induction on neurons and 
axons makes these cells viable targets for immunological attack.  
 
Fig. 3. A CD8+ cytotoxic T cell (blue) apposed to a demyelinated axon (green). The cytotoxic 
granules (light blue and arrowhead) are polarized toward the surface of the axon, indicating 
an “immunological synapse” (from Neumann et al., 2002). 
7.3 Nitric oxide intermediates 
Activated microglia and macrophages are readily seen surrounding and engulfing 
degenerating axons and end-bulbs (Lassmann, 2003). These monocytes are thought to 
introduce toxic effector molecules capable of damaging axons. Two of these that have been 
identified are proteases and reactive nitrogen species. Proteases degrade intracellular 
structural elements, causing disturbances in fast axonal transport (Anthony et al., 1998). 
High levels of nitric oxide (NO) radicals have been identified in MS lesions (Smith and 
Lassmann., 2002). NO radicals cause injury to mitochondria and disrupt axonal 
cytoarchitecture (Smith et al. 2001; Smith and Lassmann, 2002). NO radical-induced 
mitochondrial injury reduces generation of ATP and, if exceeding a certain threshold, 
triggers apoptotic mechanisms by cleavage and activation of caspases. Also, reactive 
nitrogen species disrupt the permeability of the axonal membrane, causing an influx of 
extracellular ions and axonal swelling. At low concentrations, NO species have been shown 
to block impulse conduction in axons even in the absence of structural damage (Redford et 
al., 1997). This demonstrates how clinical deficit may manifest in MS patients before 
dramatic degenerative changes are detectable in axons (Lassmann et al., 2003). Because 
reactive nitrogen species can also cause demyelination and oligodendrocyte damage, these 
substances fit well into the pathogenetic sequence of events in MS (Lassmann et al., 2003). In 
line with this concept, early structural changes in mitochondria and oxidative DNA damage 
has recently been implicated in axonal injury preceding demyelination (Nikić et al., 2011; 
Haider et al., 2011). 
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Fig. 4. A CD8+ CTL recognizes MHC-I on an MS axon and releases effector substances. 
Granzyme helps degrade the intracellular fast transport network. Perforin inserts into the 
axoplasmic membrane and allows Na+ to freely diffuse into the cell. Rising intracellular 
Na+ leads to detrimental effects in the axon. 
7.4 Demyelination  
The loss of myelin and glia causes severe dysregulation of physiologic and homeostatic 
mechanisms in axons ultimately ending in cell death. The duration from onset of injury to 
neuronal death depends on compensatory and reparative mechanisms of the cellular milieu 
of the CNS in addition to the extent further inflammatory reactions accelerate the process. 
The most striking evidence that loss of myelin is behind neurological progression in MS are 
post-mortem histological studies showing the tight correlation between inflammatory 
demyelination and axonal loss (Frischer et al., 2009). Strong support also comes from 
experiments showing that myelin-protein deficient mice lose axons over time (Griffiths et al., 
1998). The relative slowness of axonal loss in these mice is comparable to the course of 
neurodegenerative progression in MS (Nave and Trapp, 2008). Further evidence includes 
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histological data showing a 60-70% reduction in axonal density in chronically demyelinated 
lesions compared with normal tissue of the same area, and a 30% reduction in fresh lesions 
(Mews et al., 1998). A similar percentage is seen in the spinal cord when the absolute number 
of nerve fibers are counted in a tract (Bjartmar et al., 2000).  
7.5 Energy imbalance in demyelinated axons 
A state of energy imbalance is the hallmark predecessor to cell death. Because demyelinated 
axons are in a state of increased demand and decreased generation of energy in the form of 
ATP, chronic energy imbalance might significantly contribute to axonal loss in MS. In 
demyelinated axons, Na+ channels become diffusely arrayed along the cell surface in 
contrast to normal clustering around nodes of Ranvier (Figure 5, Craner et al., 2004; Black et 
al., 2007b). These axons have an increased energy requirement per action potential. 
Disruption of ion transport caused by cytoarchitectual disturbances further increases the 
metabolic load of the axon. Simultaneously, various pathologic mechanisms reduce 
generation of ATP. These mechanisms include disruption of the mitochondrial membrane 
by ambient nitric oxide and free radicals as well as down-regulation of mitochondrial 
protein transcripts (Mahad et al., 2008). Using novel multiphoton imaging technology, a 
recent study identified mitochondrial pathology taking place within axonal swellings 
ensheathed with normal myelin in an animal model of multiple sclerosis (Nikić et al., 2011). 
This data shows that energy imbalance in the axon can occur even in the absence of local 
demyelination.  
Energy imbalance in the demyelinated axon leads to a reduction in protein synthesis and 
fast axonal transport. The cytoplasmic density of Na+/K+ATPase exchanger drops, and 
consequently the electrochemical gradient critical to the functionality and survival of the cell 
is compromised (Young et al., 2008). The cell is overwhelmed with inrushing Na+ and is 
unable to compensate. Rising intracellular Na+ triggers a reversal of the Na+/Ca++ 
exchanger, leading to a Ca++mediated neurodegenerative cascade of events not unlike those 
seen in ischemia. This deleterious state has been called virtual hypoxia. 
7.6 Oligodendrocyte decimation 
The oligodendrocyte is an extraordinary glial cell derived from neuroepithelial stem cell 
progenitors. Its characteristic arbor projects numerous angular processes capable of 
myelinating up to 40 nerve axons (Weinshenker, 1994; Weiner, 1998; Compston and Coles, 
2002). Classically oligodendrocyte processes wrap around the cell membrane of axons and 
produce concentric myelin layers. After myelination takes place, oligodendrocyte processes 
retain their physical connection with the myelin sheath of axons. In vitro studies using 
human oligodendrocytes and neurons cultured concomitantly show that molecular trophic 
factors released by oligodendrocytes significantly impact the survival and proliferation of 
axons (Wilkins et al., 2003). Moreover, small molecule secretions by neurons and axons are 
thought to influence the structural viability and intracellular mechanisms of local 
oligodendrocytes well after the myelination phenomenon. Therefore, a bidirectional trophic 
interplay between neurons and oligodendrocytes supports the healthy maintenance of both 
these cell populations.  
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Fig. 5. MS spinal cord axons lacking myelin (green) exhibit increased expression of Na+ 
channels (red) along their surfaces. Panels A–B: Control spinal cord shows heavily 
myelinated fibers with (A) Nav1.6 channels concentrated at nodes of ranvier and (B) no 
detectable Nav1.2 sodium channel staining. Panels C–D: MS spinal cord shows severe 
demyelination with (A) Nav1.6 and (B) Nav1.2 sodium channels diffusely arrayed along 
naked axolemmas. Increased Na+ influx in MS axons leads to Na+/Ca++ exchanger reversal 
and subsequent degenerative changes (adapted from Craner et al., 2004). 
In MS, degenerating oligodendroyctes are numerous in white matter tissue adjacent to 
inflammatory foci and have been identified in NAWM regions distant from lesions 
(Henderson et al., 2009). In both lesions and NAWM regions, oligodendrocyte processes “die 
back” from the axonal myelin sheath in some cases (Lucchinetti et al., 2000). It is unclear 
whether the dying back phenomenon is resultant from contact with degenerating axons or 
dystrophy intrinsic to the oligodendrocyte. It is clear, however, that the environment of the 
MS lesion has a profound affect on oligodendrocyte survival. Compared to NAWM in both 
MS patients and controls, chronic lesions contained markedly decreased numbers of 
oligodendrocytes and oligodendrocyte progenitor cells (Kulmann et al., 1999). Disruption in 
the secretion, integrity, and uptake of trophic factors released and/or delivered by neurons 
and glia might contribute to the oligodendrocyte demise in MS. Other possibilities include 
NO-mediated cytotoxicity, T cell-induced killing, or the presence of a currently unknown 
toxin or virus affecting oligodendrocyte health. Our group is currently studying molecular 
profiles of MS oligodendrocytes in order to find out what factors influence their survival. 
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7.7 Dissolution of the axonal cytoskeleton 
As described above, various mechanisms interface to ultimately bring intracellular Ca++ 
concentrations to dangerous heights. These mechanisms include direct T cell-mediated 
axonal injury, diffusion of Na+ channels along demyelinated internodal regions of axons, 
and free radical-mediated increased membrane permeability and mitochondrial damage. 
Reduction in mitochondrial output establishes an energy imbalance within the cell, leading 
to stalled fast axonal transport and skewed ion channel densities in the axonplasmic 
membrane. Rising intracellular Ca++ activates Ca++ dependent proteases which degrade 
the axonal structural framework. The activity of ambient proteases and the loss of trophic 
factors from oligodendrocytes are thought to amplify this degenerative process in the MS 
lesion environment (Anthony et al., 1998, Wilkins et al., 2003). The active disintegration of 
the intra-axonal microtubule network and decreased ATP availability stall the machinery of 
fast axonal transport. Proteins like APP accumulate, causing swelling and increased tension 
in a manner not unlike that seen in acute traumatic head injury (Povlishock, 1992). 
Furthermore, disabled fast transport arrests movement of Ca++ channel proteins along 
axonal microtubules. Subsequent insertion of these channels into the membrane results in 
Ca++ channels discontinuously arrayed along the surface of MS lesion axons (Kornek et al. 
2001). The result is a vicious cycle of Ca++ influx which eventually leads to the demise of the 
axon. The positive feedback loop of protease activation–cytoskeletal disruption–ion channel 
insertion continues as more Ca++ rushes into the cell (Smith et al., 2001). Ultimately, 
swelling and structural damage reach a point where the axonal cytoskeleton dissolves 
(Lassmann et al., 2003). The axon is transected, and conduction along the nerve fiber 
inhibited. Organelles and fast transport proteins such as APP remain and continue to 
accumulate in the terminus, causing axonal end-bulb formations with characteristic 
morphology (Povlishock, 1992).  
7.8 Wallerian degeneration 
Anterograde “Wallerian degeneration” or secondary degeneration has been proposed as a 
mechanism of axonal loss. In this process, acute ultrastructural changes at some point along 
the axon can cause degeneration in regions of the nerve fiber not immediately associated 
with the site of injury. Nerves passing through a focus of inflammatory demyelination 
might therefore manifest pathological changes distal to the injured or transected site 
(Shindler et al., 2008). In this scope, degenerating nerves in the NAWM of MS patients might 
be spatially distinct from inflammatory foci but retain an intimate link to the cellular 
changes taking place at those sites of disease activity. That is, if axons and lesion are 
contained within the same tract, secondary degeneration helps explain the loss of axons in 
seemingly unaffected white matter areas contralateral to lesioned tissue (Evangelou et al., 
2000a; Lovas et al., 2000; Evangelou et al., 2000b; Evangelou et al., 2004).  
Demyelination however is not the only pathological phenomenon in MS capable of inducing 
Wallerian degeneration. Any subtle change in cytoarchitecture, due to its effects on fast 
axonal transport, will be felt downstream. Immunological attack of axons by CD8+ CTLs is 
capable of initiating secondary degeneration in the absence of demyelination (Manning et 
al., 1987). In the same vein, NO-mediated axonal injury by monocytes could potentiate 
degenerative changes elsewhere in fiber tracts. Loss of important trophic factors can cause 
transynaptic secondary neuronal loss, which in turn leads to degeneration of the projecting 
axons (Wilkins et al., 2003). 
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8. Animal models for MS axonopathy 
8.1 Axonal injury in experimental autoimmune encephalomyelitis (EAE) 
EAE is an inducible autoimmune condition in animals characterized by T cell mediated 
inflammatory demyelination and neurodegeneration (Gold et al., 2006; Steinman and 
Zamvil, 2006). Animals are inoculated with CNS proteins often with complete Freund’s 
adjuvant (CFA) to stimulate an inflammatory reaction to myelin antigens. Pertussis toxin is 
used in these models to break down the blood brain barrier and allow immune cell 
infiltration. Depending on the protocol and animal genotype, EAE can follow a monophasic, 
relapsing/remitting, or chronic course. In mice, symptoms usually become apparent within 
2 weeks of inoculation. The classic first symptom is loss of tonus in the tail leading to 
paralysis, followed by loss of motor function in the hind and then forelimbs. Symptoms 
associated with MS also present in EAE, including ataxia, optic neuritis, emotional liability, 
and cognitive dysfunction. 
Axonal pathology in EAE mice morphologically resembles changes seen in MS patients 
(Soulika et al., 2009). EAE mice induced by immunization with myelin oligodendrocyte 
protein (MOG) peptide 35-55 show axonal vacuolization and fragmentation, as well as brain 
atrophy (Bannerman et al., 2005; Wang et al., 2005; Bannerman and Hahn, 2007; Herrero-
Herranz et al., 2008; Jones et al., 2008). C57BL/6 mice immunized with MOG in CFA exhibit 
intra-axonal accumulations of APP and hyperphosphorylated heavy chains (NF-H). 
Neurological deficits manifest clinically in EAE mice at approximately the same time as 
characteristic SMI32+ spheroids are detectable in spinal cord axons (Figure 6, Soulika et al., 
2009). These spheroids contain high concentrations of Toll-like receptor 8 (TLR8) protein 
(Soulika et al., 2009) shown to cause neuronal death via apoptosis and inhibit neurite 
formation (Ma et al., 2006, 2007). In this same EAE model, innate immunity infiltrates are 
detectable early on in the disease course. Neutrophils in the early innate immunological 
wave permeabalize the blood brain barrier and perform neurotoxic effector functions via a 
contact-dependent, protease-mediated mechanism (Dinkel et al., 2004). Moreover, a 
progressive, symmetric, severe loss of small diameter dorsal corticospinal axons is evident 
approximately 3 months post-innoculation (Soulika et al., 2009). At this time, inflammation 
is diminished to the level of controls, while genes associated with the activation of innate 
immunity continue to be expressed (Soulika et al. 2009). These data indicate that the innate 
arm of the immune system may play a key role in late-onset axonal loss in the MOG-
induced EAE model (Weiner, 2009). 
8.2 Neurodegeneration in mice lacking expression of 2’-3’-cyclic nuclotide 3’-
phosphodiesterase (CNP) 
CNP is an intrinsic protein of oligodendrocytes associated with cytoskeletal elements 
(Nishizawa et al., 1985) and detectable in purified myelin (Kurihara et al, 1967). 
Engineered mice deficient in CNP (CNP–/–) display profound axonal loss, leading to a 
severe neurodegenerative disorder and premature death (Lapp-Siefke et al., 2003). This 
animal model demonstrates that oligodendrocytes provide support for axons independent 
of the physical stability of myelin itself. Degenerating neurons of CNP–/– mice display 
pathologic changes characteristic of MS (Povlishock, 1992) including axonal swellings 
filled with microtubules, dense bodies, multivesicular bodies, and mitochondria. These 
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cells were associated with phagocytic activity, reminiscent of macrophages and microglia 
often surrounding dystrophic axons in MS lesions. Moreover, the progressive 
neurological decline of CNP–/– mice is not unlike that seen in progressive MS patients. 
During the first 3 months, the knockout strain is indistinguishable from wildtype. This 
brings to mind the proposed clinical silence of the neurodegenerative component of MS 
preceding the progressive phase of the disease (Bjartmar and Trapp, 2003; Kremenchutsky 
et al., 2006). At 4 months CNP–/– mice begin to show hindlimb impairments, convulsions, 
and ataxia. At 6 months, the mice are unable to grasp a round bar with their hindlimbs, 
and display a reduction in overall brain size. Less than 20% of CNP–/– mice reach 13 
months. Those that do are unable to balance on a round bar for 1 second, and exhibit 
profound muscle weakness, weight loss, gait abnormalities, and kyphosis. The CNP–/– 
strain is of promising value to the MS research community. Not only does the model 
uncouple axonal loss from structurally intact myelin (demyelination), but it also 
demonstrates a relationship between intracellular processes of the oligodendrocyte and 
axonal survival. 
 
Fig. 6. Axonal spheroids (arrowhead) are evident in spinal cord axons in a mouse model of 
MOG-induced EAE. Although demyelination of the tract is evident, many of the spheroids 
are encircled with intact myelin (long arrow). This pathology is consistent with axonal 
changes in MS (adapted from Soulika et al., 2009). 
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9. Overview of therapeutic strategies to counteract neuronal-axonal loss in 
MS 
Developments in our understanding of axonal loss in MS have spearheaded the relatively 
recent realignment of our thinking about the disease as a neurodegenerative as well as 
immune-mediated disease process. The increased understanding of axonal loss in MS has 
opened exciting research avenues geared toward developing novel therapies. These 
therapies aim to increase neuroprotection, enhance the remyelinating capacity of the CNS, 
and address the incongruity of trophic support supposed in the multiple sclerosis CNS 
environment by replacing both important molecules and decimated cell populations. 
Elucidating the mechanisms of nerve degeneration and how they interface with 
inflammatory demyelination during the biphasic clinical course of MS remains a critical step 
toward therapeutic victory over the disease.  
9.1 Remyelination 
The brain has evolved mechanisms to counteract axonal degeneration. Most of the 
reparative focus is on rebuilding the myelin architecture devastated by the inflammatory 
milieu (Prineas et al., 1993). Oligodendrocytes are responsible for repairing demyelinated 
axons through a process called remyelination. By repairing ultrastructural deficits 
accumulated through loss of myelin, remyelination not only partially restores saltatory 
conduction (Kriss et al., 1988) but also ameliorates degenerative processes occurring 
elsewhere in the axon such as secondary Wallerian degeneration (Irvine et al., 2008). In line 
with this, patients with robust remyelination live longer compared to patients showing few 
remyelinated brain regions (Patrikios et al., 2006).  
Chronic MS disease processes diminish the ability for specific brain regions to remyelinate 
(Hanafy and Sloane, 2011). For example, hyaluronic acid accumulates in chronic MS lesions 
and inhibits remyelination and oligodendrocyte progenitor maturation (Figure 7, Sloane et 
al., 2010b). Activation of other molecular cascades such as the Notch1 pathway, Wnt 
pathway, and inflammation are thought to contribute to remyelination blockade (Hanafy 
and Sloane, 2011). The consequence of this is failure of the axon to successfully remediate 
injury and energy imbalance, further instigating dystrophic changes, transection, and 
secondary degeneration. A large sector of MS research is geared toward developing 
therapeutics that promote and amplify remyelination in MS. Strategies include enhancing 
oligodendrocyte proliferation and progenitor recruitment in chronic lesions (Patel et al., 
2010), grafting exogenous oligodendrocyte progenitor cells in proximity to affected tissue 
(Wang et al., 2011), and blocking or genetically deleting receptors that inhibit remyelination 
(Mi et al., 2007; Sloane et al., 2010b). These efforts center around the idea that boosting 
remyelination capacity in MS patients would ameliorate long-term clinical outcomes and 
provide neuroprotection against progressive disease. 
9.2 Na+ channel blockers 
Increased Na+ influx into axons creates a state of virtual hypoxia in MS axons and 
contributes to axonal dissolution (Waxman, 2008). Irregular densities of Na+ channels 
detectable along demyelinated axons (Black et al., 2007a) along with altered expression of 
Na+ channels in MS neurons provide strong support for this idea (Craner et al., 2004). 
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Building on these observations, in vitro experiments show that selective Na+ channel 
blockers can prevent axonal injury from anoxia and ischemia (Stys et al., 1992a, 1992b, 1996; 
Fern et al., 1993; ). Using a MOG-induced EAE mouse model, Lo et al. showed that 
administration of the Na+ channel blocker phenytoin ameliorates 28-30 day clinical 
outcomes in EAE and reduces loss of corticospinal axons from 63% to 28% (Lo et al., 2002). 
Other studies have verified the neuroprotective effects of Na+ channel blockers in EAE 
(Bechtold et al. 2004). Moreover, phenytoin-treated mice in the Lo et al. study displayed 75% 
less inflammatory infiltration than normal EAE mice, possibly accounting for the 
dramatically improved clinical scores. This reduction has been attributed to hyperdensities 
of sodium channels on activated macrophages and microglia in the CNS of EAE mice 
(Craner et al., 2005). Blockage of Na+ channels presumably curtails neurotoxic immune 
effector functions of these cells, including NO radical production and phagocytosis, and 
diminishes immune-mediated axonal destruction. Infiltrating monocytes in MS lesions also 
show increased sodium channel expression (Craner et al., 2005). At present, three large scale 
phase-I human clinical trials have been launched to examine the efficacy of Na+ channel 
blockers in treating different stages of MS (Waxman, 2008). However, the progress of these 
trials has been disturbed by emerging evidence of acute disease exacerbation following 
withdrawl of Na+ channel blocker therapy. Black et al. found that EAE mice treated with 
phenytoin experienced marked inflammatory infiltration and increased vascular 
permeability once the drug was removed, with death occuring in approximately 50% of 
these mice (Black et al., 2007).  
 
Fig. 7. MS axon passing through a chronic MS lesion. Oligodendrocytes migrate into the 
lesion environment to replace lost myelin on the axon (remyelination). Hyaluronan 
accumulates in the chronic MS lesion, preventing oligodendrocyte maturation and possibly 
influencing migration into the lesion.  
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9.3 Preventing free radical damage 
NO is a double-edged sword in MS. On the one hand, NO is thought to modulate 
immunological functions. For example, prevention of NO production has been shown to 
exacerbate some forms of EAE (Giovanni et al., 1998). On the other, NO-associated free radical 
damage has been implicated in the pathogenesis of axonal loss in MS and the clinical 
manifestations of the disease (Redford et al., 1997; Smith et al., 2001, 2002). NO can be 
converted into reactive nitrogen species, such as peroxynitrate (ONOO(-)), and inflict cellular 
damage (Jack et al., 2007). In EAE, inducible nitric oxide synthase (iNOS) shows up in 
perivascular macrophages before demyelination, and is associated with transient functional 
disturbance in axons (Aboul-Enein et al., 2006). This brings to mind early, reversible 
pathological changes seen in axons before inflammatory demyelination (About-Enein et al., 
2006; Nikić et al., 2011). Furthermore, iNOS is highly expressed in actively demyelinating, 
remyelinating, and chronic MS lesions, and is extensive in normal brain matter regions (Hill et 
al., 2004; Broholm et al, 2006). Because of these findings, blocking formation of reactive 
nitrogen species may be an attractive therapeutic target for the treatment of axonal loss in MS.  
The neuroprotective ability of the drug glatiramer acetatate (GA, trade name Copaxone) is 
under active investigation. Subcutaneous injection of GA is currently used for the treatment 
of relapsing/remitting MS. GA is thought to work by inducing Th2/3 cells to cross the 
blood brain barrier, accumulate in the CNS, and express IL-10, TGF-, and neurotrophic 
factors such as brain-derived neurotrophic factor (BDNF) (Aharoni et al., 2003). GA has been 
reported to prevent free radical formation in peripheral blood adherent mononuclear cells in 
vitro (Iarlori et al., 2008). One of these radicals, superoxide anion (O(2)(-)), reacts with NO to 
produce peroxynitrate. Peroxynitrate has been associated with extensive oligodendrocyte 
cell death in a subset of MS lesions (Jack et al., 2007). Early animal studies on the 
neuroprotective effects of GA show promise. Spinal cords of glatiramer acetate-treated EAE 
mice show significantly reduced demyelination and enhanced remyelination compared to 
controls (Aharoni et al., 2008). Moreover, when treatment was initiated at the time of 
manifestation of clinical symptoms, or even in the chronic disease phase when extensive 
demyelination had already accumulated, GA dramatically reduced pathological damage. 
Randomized human clinical trials measuring disease activity and burden using state-of-the-
art imaging technology are currently investigating the neuroprotective effects of GA 
treatment in MS patients (García-Martín et al., 2010). As more is discovered regarding the 
pathogenesis of axonal loss and mechanisms of substances such as GA, selectively shutting 
down the neurodegenerative machinery of MS will become more feasible.  
10. Conclusion 
Since Charcot’s identification of axonal pathology in MS in 1869, two main attributes of the 
disease are clear. First, independent of the relapsing/remitting phase of MS, a pathologic 
process of accumulating axonal loss is chiefly responsible for the currently untreatable 
neurological decline in MS. Second, although it might not be the causative factor, 
inflammation definitely spatiotemporally coincides with the extent of axonal injury in 
affected tissue. The presence of cytotoxic CTLs targeted against axons, free radical-induced 
mitochondrial damage, and mislocalization of membrane ion channels point to an etiology 
that is immunological in nature. Loss of oligodendrocyte trophic support or other protective 
functions also cannot be disregarded as a cause of axonal dystrophy.  
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Brain cells are capable of releasing endogenous ligands in response to cellular damage 
which activate innate and cellular immune responses (Matzinger, 2002; Sloane et al., 2010a). 
Recent evidence shows that, in an EAE mouse model, axonal dystrophy can occur in pre-
lesion areas before hits of inflammatory demyelination (About-Enein et al., 2006; Nikić et al., 
2011). Moreover, axonal swellings in these areas often spontaneously resolve with no 
induced inflammation (Nikić et al., 2011). It is possible that individual axons manifest 
dystrophic changes in the absence of inflammation and as a result release danger signals 
into the exocellular environment (Matzinger, 2002). Further axonal injury may amplify or 
modulate these chemical messengers until reaching a threshold that induces inflammation. 
Instigated innate and cellular immune effector cells target degenerating axons expressing 
MHC, resulting in active inflammation that amplifies structural damage to axons.  
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